Synaptic Ras GTPase-activating protein 1 (SYNGAP1) (SYNGAP1)

Synaptic Ras GTPase-activating protein 1 (SYNGAP1) is a critical enzyme and scaffolding protein located primarily in the postsynaptic density of excitatory neurons. It acts as a negative regulator of Ras and Rap GTPases, which are essential for modulating synaptic strength and the structural maturation of dendritic spines [UniProt, NCBI Gene]. Proper expression of the SYNGAP1 protein is vital for neurodevelopment, as it controls the transition of silent synapses to active ones and regulates the trafficking of AMPA receptors to the cell surface [PubMed]. Mutations in the SYNGAP1 gene typically lead to haploinsufficiency, resulting in a condition known as SYNGAP1-related intellectual disability (SRID) or SYNGAP1 encephalopathy. This syndrome is characterized by cognitive impairment, early-onset epilepsy, and behavioral challenges associated with autism spectrum disorder [NIH, SYNGAP1 Foundation]. From a therapeutic perspective, SYNGAP1 is a major target for precision medicine, with current drug development focusing on antisense oligonucleotides (ASOs) and gene therapies designed to increase functional SynGAP protein levels in the brain [Stoke Therapeutics, PubMed]. Managing the precise dosage of SynGAP is crucial, as both deficiency and potential overexpression can disrupt the delicate balance of excitatory and inhibitory signaling in the central nervous system.

Other names

SynGAPRas GTPase-activating protein SynGAPRASA5MRD5SYNGAP1-related intellectual disabilityMental retardation autosomal dominant 5

Upregulation of protein expression through antisense oligonucleotides (ASOs), promotion of protein stability, and gene replacement therapy to compensate for haploinsufficiency [Stoke Therapeutics, PubMed].